# Burping, Reflux and Gas on a GLP-1: The Label's Widest Gap

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/glp1-burping-reflux-and-gas

> Eructation runs under 1% on placebo against 7% on Wegovy: a sevenfold difference, and the widest relative gap in the adverse-reactions table. Reflux is a much smaller increase than people expect.

## Key points

- Eructation: under 1% on placebo against 7% on Wegovy, a sevenfold gap.
- Reflux is modest by comparison: 5% against 3%, smaller than most people expect.
- Zepbound's dose-stratified table shows these PLATEAU: eructation 4%, 5%, 5% across doses.
- The sulfur smell is common, but no study has measured its cause on these drugs; the usual explanation is food fermenting for longer.

Nausea gets the warnings. Burping does not, and it has the widest relative gap in the entire adverse-reactions table: **under 1%** on placebo against **7%** on Wegovy.[1] That is a sevenfold difference. Nausea, the effect everyone is told about, is under threefold. If you started one of these and found yourself burping in a way you never did before, that is the drug. It is in the label, even if nobody mentioned it.

## The numbers, side by side

*Upper-gut effects in the adult weight-management trials. Wegovy 2.4 mg against placebo (N=2,116).*

| Effect | Placebo | Wegovy | Relative gap |
| --- | --- | --- | --- |
| Eructation (burping) | <1% | **7%** | More than sevenfold |
| Dyspepsia (indigestion) | 3% | 9% | Threefold |
| Abdominal distension (bloating) | 5% | 7% | Modest |
| Flatulence | 4% | 6% | Modest |
| Gastroesophageal reflux | 3% | 5% | Modest |

Reflux needs separating from the rest. At 5% against 3% it is a real but modest increase, far smaller than the burping figure and smaller than many people expect given how much is written about it. For the questions people ask about heartburn in particular, see [our reflux and GERD Q&A](https://glpwatchdog.org/research/qna/top-glp1-reflux-gerd-questions-reddit-answered).

## Why it happens: the usual explanation, and its limits

The labels say these drugs delay stomach emptying, and the usual explanation runs from there: food that stays in the stomach longer has more time to produce gas, and puts more pressure below the valve that is supposed to keep stomach contents down. It is a plausible account, not a proven one. The authors of the pooled STEP analysis describe the cause of the stomach side effects as uncertain, note that the longer-acting drugs do not appear to delay emptying much, and point to a 20-week study of semaglutide 2.4 mg that found no measurable delay.[3]

[The sulfurous smell](https://glpwatchdog.org/research/qna/top-semaglutide-side-effect-questions-reddit-answered) many people describe is real enough, but no study has measured what causes it on these drugs. The common explanation is that food fermenting for longer produces sulfur-containing gases that the burping brings up. It is unpleasant, and on its own it is not one of the warning signs the labels list. Other odor changes, in urine, breath and sweat, are covered in [smell changes and body odor on a GLP-1](https://glpwatchdog.org/research/glp1-smell-changes-and-body-odor).

> The likeliest common thread in that table is food moving through more slowly, though for the weekly drugs that has not been proven.

## The dose question, which Zepbound's label answers

Wegovy’s table gives one dose against placebo. Zepbound’s is stratified across 5, 10 and 15 mg, which lets you see whether these effects climb with dose.[2] Mostly, they do not.

*Zepbound, by dose. Placebo / 5 mg / 10 mg / 15 mg.*

| Effect | Placebo | 5 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- |
| Eructation | 1% | 4% | 5% | 5% |
| Gastroesophageal reflux | 2% | 4% | 4% | 5% |
| Dyspepsia | 4% | 9% | 9% | 10% |

Each of these roughly doubles or triples from placebo to the lowest dose and then flattens. That is a different pattern from [fatigue](https://glpwatchdog.org/research/glp1-fatigue-what-causes-it), which keeps climbing with dose. In practice, the burping you get at 5 mg is roughly the burping you get at 15, so if you can tolerate it early, escalation is unlikely to make this particular problem much worse.

## What actually helps

No trial has tested remedies for this, so what follows rests on the mechanism and is modest.

- **Smaller meals, eaten more slowly.** A stomach that empties slowly copes badly with volume, and swallowed air makes burping worse.
- **Carbonated drinks add gas to a system already holding it.** Cutting them is an easy first change to try.
- **Fatty and very large meals sit longest.** They also drive reflux independently. So does a lot of coffee; see [coffee and caffeine on a GLP-1](https://glpwatchdog.org/research/coffee-and-caffeine-on-a-glp1).
- **Do not lie down after eating**, which is standard reflux advice and matters more when the stomach is emptying slowly.

> **Reflux to raise with a clinician, not manage alone.** Persistent heartburn, pain on swallowing, food sticking, vomiting that will not settle, or black stools are not this. Long-running untreated reflux damages the esophagus, and a drug that slows gastric emptying is a reason to take it more seriously. Mention it before any procedure with sedation, too (see [holding a GLP-1 before endoscopy](https://glpwatchdog.org/research/glp1-before-endoscopy-and-surgery)). Stomach pain, as opposed to burning, is a separate question, and [GLP-1 stomach pain: what is expected and what is a warning sign](https://glpwatchdog.org/research/glp1-stomach-pain-when-to-worry) sets out the patterns the labels single out.

For the effects further down the same system, our [constipation guide](https://glpwatchdog.org/research/glp1-constipation-what-works) covers what the labels report and what the evidence supports, and [how long side effects last](https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last) covers the escalation-week pattern most of them follow. Whether a [low-FODMAP diet](https://glpwatchdog.org/research/low-fodmap-diet-on-a-glp1) helps with gas and bloating on these drugs is untested; what it does in IBS is set out there.

## Frequently asked questions

### Why am I burping so much on a GLP-1?

The usual explanation is that the drug slows the stomach, so food sits longer and produces more gas, although that has not been proven for the weekly drugs. The label puts eructation at under 1% on placebo against 7% on Wegovy. That sevenfold difference is the widest relative gap in the whole adverse-reactions table.

### What causes the sulfur smell?

No study has measured it on these drugs. The usual explanation is that food staying longer in the stomach produces sulfur-containing gases, which burping brings up. On its own it is not one of the warning signs the labels list; stomach pain that is severe or will not go away is, and is covered in our guide to GLP-1 stomach pain.

### Do these drugs cause acid reflux?

Modestly. The Wegovy label reports gastroesophageal reflux in 5% against 3% on placebo, and Zepbound's dose-stratified table runs 2% on placebo against 4–5% across its doses. The increase is real, but much smaller than the burping figure and smaller than many people expect.

### Will it get worse as my dose goes up?

Probably not much. Zepbound's table shows these effects roughly doubling or tripling from placebo to the lowest dose and then flattening: eructation runs 4%, 5% and 5% across 5, 10 and 15 mg. That differs from fatigue, which keeps climbing.

### When is reflux a reason to call someone?

Persistent heartburn, pain on swallowing, a sense of food sticking, vomiting that will not settle, or black stools. Long-running untreated reflux damages the esophagus. Flag it, too, before any procedure involving sedation.

## References

1. Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 6.1 Adverse Reactions: eructation, dyspepsia, abdominal distension, flatulence and gastroesophageal reflux disease (revised 06/2026). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. Eli Lilly and Company. ZEPBOUND (tirzepatide) — US Prescribing Information, Section 6.1 Adverse Reactions, dose-stratified table (SPL effective 2026-04-22). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
3. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism. 2022. PMID: 34514682. https://pubmed.ncbi.nlm.nih.gov/34514682/

---

Cite as: GLP Watchdog, Ruth Calder, "Burping, Reflux and Gas on a GLP-1: The Label's Widest Gap", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/glp1-burping-reflux-and-gas

Canonical HTML page: https://glpwatchdog.org/research/glp1-burping-reflux-and-gas

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
